Freny Mody
Cardiovascular Disease · Los Angeles, CANPI 1639198583
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (48.9%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Novartis Pharma AG at 35.6% of the total. Reporting peaked in 2019 at $16,498 and has fallen 98.1% since, to $306 in 2025.
Across 79 payments — averaging $306.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Pharma AG$9K
- AstraZeneca$5K
- Vifor Pharma, Inc.$4K
- Scpharmaceuticals Inc.$2K
- CSL Behring$947
- Cvrx, Inc.$879
- plus $2K from 13 others
Across 129 payments — averaging $7260.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$355K
- Livanova USA, Inc.$168K
- Merck$121K
- AstraZeneca$98K
- Novartis$71K
- Astrazeneca UK Limited$56K
- plus $66K from 5 others
What the payments were for
- Consulting fees$4,70019%
- Speaking & faculty fees$4,05017%
- Travel & lodging$11,83449%
- Food & beverage$3,34014%
- Education$2671%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Pharma AG | 7 | $8,621 |
| AstraZeneca | 15 | $5,063 |
| Vifor Pharma, Inc. | 10 | $4,447 |
| Scpharmaceuticals Inc. | 5 | $2,296 |
| CSL Behring | 6 | $947 |
| Cvrx, Inc. | 8 | $879 |
| Impulse Dynamics (USA) Inc. | 4 | $492 |
| Novo Nordisk | 10 | $371 |
| Regeneron Healthcare Solutions, Inc. | 2 | $235 |
| Merck | 3 | $140 |
| Abbott | 1 | $127 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Amarin Pharma, Inc. | 1 | $118 |
| Boehringer Ingelheim | 1 | $111 |
| Pfizer | 1 | $56 |
| Amgen | 1 | $50 |
| Akcea Therapeutics, Inc. | 1 | $44 |
| Johnson & Johnson | 1 | $40 |
| Esperion Therapeutics, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LCZ696G_ENTRESTO_CARDIOVASCULAR$8,481
- FARXIGA$4,703
- Veltassa$4,003
- FUROSCIX$2,118
- OPTIMIZER$916
- Barostim Neo System$632
- CardioMEMS HF System$127
- DISEASE STATE$125
- EVKEEZA$118
- Vascepa$118
How this compares
$24,191 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Los Angeles
- Cathleen Bairey-MerzLos Angeles$1.2M
- Karol WatsonLos Angeles$553K
- Jamil AboulhosnLos Angeles$423K
- Darren BermanLos Angeles$392K
- Arash NayeriLos Angeles$281K
- Gregg FonarowLos Angeles$260K
- Martha GulatiLos Angeles$141K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.